J. Hartney

An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21 days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer.

B. Monk, D. Provencher, P. Rose, 2011, Gynecologic oncology.

A Phase I Study to Characterize the Safety, Tolerability, and Pharmacokinetics of Topotecan at 4 mg/m2 Administered Weekly as a 30‐Minute Intravenous Infusion in Patients With Cancer

M. Borad, D. Northfelt, P. Lebowitz, 2010, Journal of clinical pharmacology.

A Phase I Study to Characterize the Safety, Tolerability, and Pharmacokinetics of Topotecan at 4 mg/m2 Administered Weekly as a 30‐Minute Intravenous Infusion in Patients With Cancer

M. Borad, D. Northfelt, P. Lebowitz, 2010, Journal of clinical pharmacology.